Fritextsökning
Artiklar per år
Innehållstyper
-
Noxious parasite forms hybrids and deceives the immune system
The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to deceive the immune system by forming new variants that are mixtures of different strains.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
New rules for diagnostic products, but who will certify them? “An extreme shortage area”
In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and Covid-19. However, not one single institute in the entire Nordic region is able to certify the diagnostics companies’ products according to the new regulations. “In the end, it risks affecting patients,” says Anna Lefèvre Skjöldebrand, CEO of Swedish Medtech.
-
Paolo Macchiarini in court – “The sole intent was to cure”
Paolo Macchiarini’s surgical procedure was illegal, life-threatening and caused severe and prolonged suffering to patients the prosecution claimed when the trial against the Italian surgeon began on Wednesday last week.
-
Bicos vd i blåsväder – uppgav fel utbildning
Det blåser kring medtechbolaget Bico. Förra veckan meddelade finanschefen Gusten Danielsson att han avgår med omedelbar verkan och på stämman röstade han mot att bevilja styrelsen ansvarsfrihet. Nu har felaktiga uppgifter om vd:n Erik Gatenholms utbildning uppdagats, rapporterar DI.
-
Rapport: ESS ekonomiskt positivt för Sverige
2021 fick två professorer i uppdrag att analysera de samhällsekonomiska effekterna av bygget av forskningsanläggningen ESS i Lund. Rapporten visar att svenska företag har stått sig väl i konkurrensen om ordrar från ESS.
-
When carelessness, forgetfulness and coincidence become the researcher’s best friend
Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advances have come about thanks to completely random incidents and the open-mindedness of scientists who were ready to think outside the box.
-
This is how Anette Steenberg will put Medicon Valley on the world map
Anette Steenberg has been CEO of the Swedish-Danish life science cluster Medicon Valley Alliance since 1 November last year. Life Science Sweden called her to ask about her visions and the challenges of merging the worlds of Swedish and Danish life science.
-
Björn Ursing: Physicians new role in AI driven healthcare
”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians changes in the era of AI.
-
Orexo får ny finanschef
I september börjar Fredrik Järrsten som CFO hos läkemedelsföretaget Orexo. Han kommer även att ingå i ledningsgruppen.
-
Elicera develops CAR-T against solid tumours – may become the first in the world
Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method. “Almost half of them have become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.
-
Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages
For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridiculed by the medical establishment. However, from our perspective today, we can sum it up with the saying: He who laughs last laughs best, writes Samuel Lagercrantz in an editorial.
-
Björn Arvidsson: ”We need to change perspective”
If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network will generate as many versions as the people you ask. Most likely, we will miss many
-
Daniel Forslund: ”Vården är inte digital eller fysisk – den är både och”
Vid årsskiftet lämnade han politiken för att hans fd parti Liberalerna gick på snedden med hans värderingar. Nu har han fått nytt jobb som utvecklingsansvarig för digitalisering hos Vårdföretagarna.
-
Tusentals ryska forskare kräver att Putin avslutar sitt krig mot Ukraina
Mer än 5 000 ryska forskare och vetenskapsjournalister har skrivit under ett öppet brev med kritik mot den ryska invasionen av Ukraina.
-
Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation
A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure that new medicines will be available for all citizens in Europe, writes Marie Gårdmark in a column.
-
Nystartade Cardo Health tar in Masha Feigelman som vice vd
Det digitala vårdbolaget Cardo Health startade som ett börsbolag under hösten 2021. Grundare är Tobias Strålin, tidigare partner på McKinsey. Nu rekryterar bolaget Masha Feigelman som vice vd. Hon får också titeln medgrundare.
-
Study: An objective diagnosis of constant tinnitus may be possible
A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tinnitus, which was demonstrated in a study made by researchers at the Karolinska Institute.
-
“Together Stockholm-Uppsala and Medicon Valley can make Scandinavia a leading life science region”
“Denmark, Sweden, Norway and Finland all have national life science strategies, but the Swedish strategy is the only one explicitly emphasizing the Nordic dimension. But what if the leading life science nations, Denmark and Sweden, joined forces, took the lead and pioneered Nordic life science collaboration? Wouldn´t we then be able to "bake a bigger cake?", writes Anette Steenberg and Ulf G. Andersson in a debate article.
-
"Vår nisch är att lösa problem"
Business Officer i bolaget.
-
The route to vaccines for everyone: “We did not just sit around and wait”
The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a proposal, and Richard Bergström did not hesitate. “I already had a notion that this would work,” he says in an interview with Life Science Sweden.
-
Boost Pharma byter vd – fortsätter utveckling av behandling mot medfödd benskörhet
Det danska cellterapibolaget Boost Pharma har utsett Evert Kueppers till ny vd. Bolaget utvecklar läkemedel mot medfödd benskörhet och bygger vidare på forskning från Karolinska institutet.
-
Giulia Gaudenzi: Innovation for good
"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences", writes Giulia Gaudenzi in a column.
BREAKING